NCT03970538进行中（未招募）不适用
Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: the PROMISE II Trial
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 105
- 试验地点
- 42
- 主要终点
- Amputation Free Survival (AFS)
研究概览
简要总结
The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").
详细描述
The objective of this US pivotal trial is to investigate the safety and effectiveness of The LimFlow System for creating an AV connection in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach to arterialize the pedal veins for the treatment of chronic limb-threatening ischemia (CLTI) in subjects ineligible for conventional endovascular or surgical limb salvage procedures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be ≥18 and ≤ 95 years of age
- •Clinical diagnosis of chronic limb-threatening ischemia, defined as any of the following clinical assessments: previous angiogram or hemodynamic evidence of severely diminished arterial inflow of the index limb (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg) and
- •Rutherford Classification 5, ischemic ulceration or
- •Rutherford Classification 6, ischemic gangrene
- •Subject has been assessed by the principal investigator, reviewed by the Independent Review Committee (IRC), and determined that no conventional distal bypass surgical or endovascular therapy for limb salvage is feasible due to either a) absence of a usable pedal artery target (endovascular or surgical approach), or b) the presence of a pedal artery target with absence of a viable single-segment vein in either lower extremity or either arm that could be used for autogenous vein conduit.
- •Proximally, the Target In-flow Artery at the cross-over point must fall within the recommended vessel diameter ranges for the LimFlow stent graft by visual estimation.
- •Prior stent(s) to the infrainguinal arteries (e.g. iliac, SFA, and popliteal) are allowed.
- •Planned minor amputation (e.g. partial toe, ray or proximal foot/transmetatarsal) of target extremity within 30 days after the index procedure is allowed.
- •Subject is willing and able to sign the informed consent form.
- •Subject is enrolled in an acceptable wound care network and has an adequate support network to ensure that subject is compliant with medication regimen and follow-up study visits.
- •Prior to enrollment (7-day window), women of childbearing potential must have a negative pregnancy test.
- •Primary wound is stable (e.g. not rapidly deteriorating and/or showing signs of healing)
- •Stable glycemic control, HbA1C < 10% (<269mg/dL)
- •Subjects requiring dialysis may be included, provided they meet all the following requirements:
- •On dialysis for > 6 months
- •Autologous arteriovenous (AV) fistula or peritoneal access used for hemodialysis
- •Serum albumin > 30 g/liter
- •BMI > 20
排除标准
- •Subjects will be excluded from participating in this study if they meet any of the following criteria prior to initiation of the endovascular procedure: Concomitant hepatic insufficiency, thrombophlebitis in the target limb, or non-treatable coagulation disorder within the past 90 days.
- •Active immunodeficiency disorder or currently receiving immunosuppressant therapy for an immunodeficiency disorder.
- •Prior peripheral arterial bypass procedure above or below the knee which would inhibit proximal inflow to the stent graft or interventional revascularization procedure within 30 days.
- •Previous major amputation of the target limb or presence of a wound requiring a free flap or absence of adequate viable tissue.
- •Life expectancy less than 12 months.
- •Documented myocardial infarction or stroke within previous 90 days.
- •Active infection (e.g. fever, significantly elevated WBC count >20.0 x 109/L, and/or positive blood culture) at the time of the index procedure that may preclude insertion of a prosthesis or require major amputation (e.g. osteomyelitis proximal to metatarsals).
- •Known or suspected allergies or contraindications to aspirin or P2Y12 inhibitors, heparin, stainless steel, nitinol or contrast agent that cannot be adequately pre-treated.
- •Subject is currently taking anti-coagulants, which in the opinion of the investigator, interferes with the subject's ability to participate in the study (i.e., intermittent interruption of therapy for procedure may compromise subject's safety).
- •Lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g. vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle).
- •Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in subjects not undergoing dialysis.
- •Severe heart failure (e.g. NYHA Class IV), which in the opinion of the investigator may compromise subject's ability to safely undergo a percutaneous procedure.
- •Any significant concurrent medical, psychological, or social condition, which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator.
- •The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
- •Subject is unwilling, or unable, or unlikely for cognitive or social reasons to comply with any of the protocol or follow-up requirements.
研究组 & 干预措施
Treatment Arm
Experimental
Treated with the LimFlow System
干预措施: LimFlow System (Device)
结局指标
主要结局
Amputation Free Survival (AFS)
时间窗: 6 months post-procedure
freedom from major amputation and death at 6 months, compared to a historical performance goal.
次要结局
- Change in Rutherford Classification(6 months post-procedure)
- Target Wound Healing(12 months post-procedure)
- Contrast Volume(During the procedure)
- Primary Assisted Patency(6 months post-procedure)
- Secondary Patency(6 months post-procedure)
- Technical Success(Immediately post-procedure)
- Primary Patency(6 months post procedure)
- All Wound Healing(12 months post-procedure)
- Limb Salvage(6 months days post-procedure)
- Procedure Time(Immediately post-procedure)
- Radiation Exposure(During the procedure)
- Procedure Success(30 days post-procedure)
- Freedom From Contrast-Induced Nephropathy(Within the first 72 hours post-procedure)
- All Wound Area Reduction(12 months post-procedure)
研究者
研究点 (42)
Loading locations...
相似试验
招募中
不适用
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening IschemiaCritical Limb IschemiaChronic Limb-Threatening IschemiaPeripheral Arterial DiseaseNCT05313165LimFlow, Inc.100
已完成
不适用
PROMISE InternationalCritical Limb IschemiaNCT03321552LimFlow SA34
已完成
不适用
Percutaneous Deep Vein Arterialization Post-Market StudyCritical Limb IschemiaNCT03807661LimFlow SA28
进行中（未招募）
不适用
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular AccessNCT06712251Venova Medical20
已完成
不适用
Totally Percutaneous Approach to Endovascular Treatment of Aortic Aneurysms (PEVAR-PRO)Aneurysm AbdominalAneurysm ThoracicAneurysm, Thoracoabdominal AorticAneurysmNCT03484013IRCCS San Raffaele320